Transformed streptomyces bacteria and method for producing bioactive substance with c-p bond
By enhancing phosphoenolpyruvate synthase activity in Streptomyces bacteria, the production of physiologically active substances with C-P bonds is significantly improved, addressing efficiency limitations in existing production methods.
Patent Information
- Application Number
- JP2023073979
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-04-28
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods for producing physiologically active substances with C-P bonds, such as bialaphos, are limited in efficiency and productivity, necessitating an enhancement in phosphoenolpyruvate synthase activity to improve production yields.
A Streptomyces bacterium is modified to enhance phosphoenolpyruvate synthase activity by overexpressing the gene encoding phosphoenolpyruvate synthase, either through increasing the gene copy number or modifying its expression control region, thereby increasing the production of substances like bialaphos, L-glufosinate, dehydrophos, and fosfomycin.
The modified Streptomyces bacterium significantly enhances the production and accumulation of physiologically active substances with C-P bonds, such as bialaphos, by promoting the consumption of phosphoenolpyruvate, a key intermediate, leading to improved productivity.
Smart Images

Figure 2024158624000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates generally to the microbial industry, and in particular to a Streptomyces bacterium having enhanced phosphoenolpyruvate synthase activity and a physiological activity having CP binding such as bialaphos. This document relates to a method for producing a substance. [Background technology]
[0002] In general, chemically synthesized pesticides are widely used as herbicides because they are stable, highly effective, and cost-effective. However, in recent years, from the viewpoint of environmental load, there is an increasing demand for herbicides derived from microbial metabolites to replace chemically synthesized pesticides. Herbicides derived from microbial metabolites are natural products, and therefore generally have the advantages of being highly biodegradable and having low environmental load.
[0003] Known herbicides derived from microbial metabolites include the amino acid herbicide bialaphos. Streptomyces It is a natural product produced by actinomycetes belonging to the genus Streptomyces, e.g., Streptomyces hygroscopicus ( Streptomyces hygroscopicus It has been reported that bialaphos can be produced by the method of fermentation (Non-Patent Document 1). It has also been reported that the productivity of bialaphos has been improved by mutation breeding (Non-Patent Document 2). [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Tachibana K. et al., 1986, Journal of the Pesticide Science Society of Japan, 11, 297-304 [Non-Patent Document 2] Takebe et al., 1995, Journal of Bioengineering, 73, 413-24 Summary of the Invention [Problem to be solved by the invention]
[0005] The present invention relates to a transformant having improved productivity of a physiologically active substance having a CP bond, such as bialaphos. The objective of the present invention is to provide a recombinant Streptomyces bacterium and a method for producing a physiologically active substance using the transformed Streptomyces bacterium. [Means for solving the problem]
[0006] The present inventors have conducted extensive research to solve the above problems, and as a result, have discovered that in bialaphos-producing bacteria, phosphoenolpyruvate (PEP), an intermediate raw material for bialaphos, and bialaphos accumulate in the bialaphos-producing bacteria. We found that there was a negative correlation between the amount of PEP and the amount of phospholipase A in the cells. From this, we hypothesized that the consumption of PEP is promoted when bialaphos is highly produced, and that by increasing the amount of PEP, we can improve the productivity of bioactive substances with CP bonds such as bialaphos. By enhancing enolpyruvate synthase activity, it is possible to inhibit CP-binding proteins such as bialaphos. The present inventors have found that this improves the productivity of physiologically active substances, and have thus completed the present invention.
[0007] The present invention provides the following: [1] A Streptomyces strain ( Streptomyces ) genus Bacteria. [2] The bacterium described in [1], which has been modified to overexpress a gene encoding phosphoenolpyruvate synthase in its cells, thereby enhancing the phosphoenolpyruvate synthase activity. [3] Increase the copy number of the gene encoding phosphoenolpyruvate synthase in cells. The bacterium according to [2], wherein the gene encoding phosphoenolpyruvate synthase is overexpressed by adding an expression control region of the gene encoding phosphoenolpyruvate synthase and / or by modifying the expression control region of the gene encoding phosphoenolpyruvate synthase. [4] The bacterium described in [2] or [3], wherein the gene encoding the phosphoenolpyruvate synthase is a polynucleotide having a base sequence of SEQ ID NO: 1, or a polynucleotide having a base sequence that hybridizes under stringent conditions to its complementary sequence and encodes a protein having phosphoenolpyruvate synthase activity. [5] The phosphoenolpyruvate synthase is a protein comprising the amino acid sequence of SEQ ID NO: 2 or an analogue of a protein comprising the amino acid sequence of SEQ ID NO: 2; The analog has an amino acid sequence having 85% or more homology to the entire amino acid sequence of SEQ ID NO:2. The bacterium according to any one of [1] to [4], wherein the bacterium is a protein having a cDNA sequence. [6] Streptomyces viridochromogenes ( Streptomyces viridochromogenes ) or Streptomyces hygroscopicus ( Streptomyces hygroscopicus The bacterium according to any one of [1] to [5], which is a bacterium belonging to the Bacillus subtilis. [7] A method for producing a physiologically active substance having a CP bond, comprising the steps of: A production method comprising culturing the bacterium according to any one of [1] to [6] in a culture medium to produce and accumulate a physiologically active substance having a CP bond in the culture medium and / or the bacterial cells. [8] The physiologically active substance having a CP bond is bialaphos, L-glufosinate, dehydrophos Selected from the group consisting of Dehydrophos, Fosfomycin and FR900098 The method for producing a physiologically active substance having a CP bond according to [7], wherein the physiologically active substance is one or more of the following: [9] The method for producing a physiologically active substance having a CP bond according to [7], wherein the physiologically active substance having a CP bond is bialaphos. Effect of the Invention
[0008] According to the present invention, by using a Streptomyces bacterium modified to enhance intracellular phosphoenolpyruvate synthase activity, it is possible to produce CP-linked phosphoenolpyruvate such as bialaphos. This makes it possible to efficiently produce physiologically active substances through fermentation. [Brief description of the drawings]
[0009]
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
[0010] In this specification, the strains with accession numbers beginning with the word JCM are registered with the Japan Collection of Microorganisms (RIKEN BioResource Center, Microbial Materials Research Center). Microorganisms stored in the Laboratory of Microorganisms (Hokkaido University, Tsukuba City, Ibaraki Prefecture, Japan, Postal Code: 305-0074, Address: 3-1-1 Takanodai, Tsukuba City, Ibaraki Prefecture) This is the number assigned to the organization and is available from the organization.
[0011] As used herein, strains having accession numbers beginning with the word ATCC can be obtained from the American Type Culture Collection (Address: 10801 University Boulevard Manassas, VA 20110, United States of America).
[0012] In this specification, the strains with accession numbers beginning with the words NBRC are registered trademarks of the National Institute of Technology and Evaluation (NITE) (Postal Code: 292-0818, Address: 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan). This is a number given to microorganisms stored in the National Institute of Informatics (NII) and can be obtained from the Institute.
[0013] In this specification, the strains having accession numbers beginning with the word DSM are registered with the Deutsche Sammlung von This is the number assigned to the microorganisms stored at Mikroorganismen und Zellkulturen GmbH (Inhoffenstr. 7B 38124 Braunschweig Germany) and can be obtained from the institution.
[0014] <1> The Streptomyces of the present invention Streptomyces ) genus bacteria The Streptomyces bacterium of the present invention is a streptomyces bacterium which has been modified so that intracellular phosphoenolpyruvate synthase activity is enhanced and which has the ability to produce a physiologically active substance having a CP bond. Leptomyces ( Streptomyces ) bacteria.
[0015] As a physiologically active substance having CP bonds, There is no particular limitation as long as the compound contains a structure having a CP bond, but bialaphos, biphenylphos, Examples of such bioactive substances include L-glufosinate, dehydrophos, fosfomycin, FR900098, and other biologically active substances having a CP bond, which are derived from phosphonopyruvate, a common intermediate in the alaphos biosynthetic pathway and has a CP bond.
[0016] "Bialaphos" is also known as phosphinothricin tripeptide (PTT) and is a phosphinothricin (PT) compound consisting of two molecules of L-alanine and one molecule of the amino acid. Bialaphos has the following chemical formula:
[0017] [ka]
[0018] The term "Bialaphos" is not limited to the free form of bialaphos, but also includes its salts or hydrates, or adducts formed by bialaphos and other organic or inorganic compounds. That is, the term "bialaphos" may refer, for example, to the free form of bialaphos or to a hydrate or adduct of bialaphos. The term "bialaphos" may include, for example, inner salts, such as sodium salts, potassium salts, ammonium salts, monohydrates, dihydrates, trihydrates, monohydrochlorides, dihydrochlorides, and zwitterions, of bialaphos acid.
[0019] Bialaphos is produced through multiple intermediates in the primary metabolic pathway of actinomycetes. The present inventors have found that the productivity of bialaphos is improved by enhancing phosphoenolpyruvate synthase activity in cells of bialaphos-producing bacteria. It is speculated that this improvement in the productivity of bialaphos is due to the increase in the amount of phosphoenolpyruvate (PEP), one of the intermediates of bialaphos, by phosphoenolpyruvate synthase.
[0020] In addition, by enhancing the activity of phosphoenolpyruvate synthase, as shown in Figure 1, not only bialaphos (referred to as PTT in Figure 1) but also its precursor, L-glufosinate, which is a stimulant for the synthesis of glycerol, and dehydrophos, which is a branch of the bialaphos biosynthetic pathway. ), Fosfomycin, FR900098, and other bioactive substances with CP bonds It is believed that the synthesis of these physiologically active substances is also improved. These physiologically active substances, like bialaphos, are substances that are biosynthesized using phosphoenolpyruvic acid as an intermediate raw material. This figure was reported in (2016), J Antibiot (Tokyo). 69, 15-25.
[0021] L-glufosinate is the following compound, which is widely used as a pesticide. When two molecules of alanine are bound to L-glufosinate, it becomes bialaphos. Note that L-glufosinate may include, for example, salts such as sodium salt, potassium salt, ammonium salt, monohydrate, dihydrate, trihydrate, monohydrochloride, dihydrochloride, and inner salts such as zwitterions. L-glufosinate is a precursor of bialaphos, and is produced by bialaphos-producing bacteria.
[0022] [ka]
[0023] Dehydrophos is the following compound, which has been reported as a fungicide (Circello BT et al., 2010, Chemistry & Biology, 17, 402-411). For example, the salts may include sodium salts, potassium salts, ammonium salts, monohydrates, dihydrates, trihydrates, monohydrochlorides, dihydrochlorides, and other salts, as well as inner salts such as zwitterions. In order to allow a Streptomyces bacterium to produce dehydrophos, it is preferable to enhance the expression of the dehydrophos biosynthetic gene cluster described in the above-mentioned literature.
[0024] [ka]
[0025] Fosfomycin is the following compound, which has been reported as an antibiotic. (Kim SY et al., 2012, Antimicrobial Agents and Chemotherapy, 56, 4175-4183). Fosfomycin may include, for example, salts such as sodium salt, potassium salt, ammonium salt, monohydrate, dihydrate, trihydrate, monohydrochloride, dihydrochloride, and inner salts such as zwitterions. In order to allow a bacterium of the genus Streptomyces to produce fosfomycin, it is preferable to enhance the expression of the fosfomycin biosynthetic gene described in the above-mentioned literature.
[0026] [ka]
[0027] FR900098 is the following compound, which is expected to be a candidate for an antimalarial drug (Eliot AC et al., 2008, Chem. Biol. 15, 765-770). FR900098 may include, for example, salts such as sodium salt, potassium salt, ammonium salt, monohydrate, dihydrate, trihydrate, monohydrochloride, dihydrochloride, and inner salts such as zwitterions. To produce FR900098 in Streptomyces bacteria, it is preferable to enhance the expression of the FR900098 biosynthetic gene described in the above literature.
[0028] [ka]
[0029] The Streptomyces bacterium of the present invention is modified so that intracellular phosphoenolpyruvate synthase activity is enhanced. As long as the activity of phosphoenolpyruvate synthase is enhanced compared to that of a non-modified strain, the bacterium may be any bacterium having any CP bond belonging to the genus Streptomyces. The bacteria may be capable of producing a physiologically active substance.
[0030] The term "bacteria producing physiologically active substances having CP binding" refers to bacteria that are cultured in a culture medium. The ability to produce and accumulate a physiologically active substance having a CP bond in the medium and / or the bacterial cells when It may refer to a bacterium of the genus Streptomyces having the ability to inhibit the growth of bacteria.
[0031] In addition, the term "bacteria producing physiologically active substances having CP bonds" refers to bacteria such as Streptomyces S. viridochromogenes ( S . viridochromogenes ) Compared to wild-type or parent strains such as JCM4977 strain In comparison, the amount of CP-bound bioactive substances produced in the medium and / or in the cells is greater than that of the control. It can also mean bacteria that have the ability to produce and accumulate CP-binding bioactive substances. The term "producing bacteria" may also refer to bacteria that can accumulate a physiologically active substance having a CP bond in a medium in an amount of, for example, 0.1 g / l or more, 0.5 g / l or more, or 1.0 g / l or more.
[0032] Streptomyces bacteria have the inherent ability to produce physiologically active substances that have CP bonds. The bacterium may be a Streptomyces bacterium that is naturally capable of producing a physiologically active substance having a CP bond, or may be modified using a mutation method or DNA recombination technology to have the ability to produce a physiologically active substance having a CP bond (for example, Non-Patent Documents 1 and 2). or a Streptomyces species imparted with the ability to produce a physiologically active substance having a CP bond In bacteria, the activity of phosphoenolpyruvate synthase can be enhanced by modifying the In addition, the Streptomyces bacterium may be one that has been modified so as to overexpress one or more genes contained in the bialaphos synthesis gene cluster that the bacterium naturally has.
[0033] The term "ability to produce a physiologically active substance having CP binding" refers to the ability to produce a physiologically active substance having CP binding when the bacterium is cultured in a culture medium. In this case, CP is present in the medium and / or the cells to such an extent that it can be recovered from the medium and / or the cells. It may refer to the ability of a bacterium of the genus Streptomyces to produce and accumulate a physiologically active substance having a binding site.
[0034] Examples of Streptomyces bacteria include, but are not limited to, Streptomyces viridomogenes ( Streptomyces viridochromogenes ), bacteria belonging to Streptomyces hygroscopicus, bacteria belonging to Streptomyces luridus, Streptomyces luridus ), a bacterium belonging to the family Streptomyces ruberomulinas ( Streptomyces rubellomurinus ) bacteria. Bacteria belonging to Streptomyces viridochromogenes or Streptomyces hygroscopicus are preferred, and bacteria belonging to Streptomyces viridochromogenes are more preferred. These naturally have bialaphos-producing ability and are capable of producing physiologically active substances with CP bonds. The bacterium of the genus Streptomyces is preferably a bacterium having the ability to
[0035] Examples of bacteria belonging to Streptomyces viridochromogenes include Streptomyces viridochromogenes JCM4977 strain, Tue57 strain (Weitnauer, G. et. al., (2002). Microbiology, 148(2), 373-379.), subsp. komabensis strain (ATCC29814), and subsp. sulfomycini strain (NBRC13830). Bacteria belonging to Streptomyces hygroscopicus include subsp. hygroscopicus (ATCC21589), subsp. ascomyceticus (ATCC14891), subsp. yingchengensis (Qin, Z. et al. (1994). J. Bacterial., 176(7), 2090-2095.), subsp. limoneus (ATCC21431), subsp. duamyceticus (JCM4427), subsp. Enhygrus (DSM41913), subsp. crystallogenes (NBRC16551), subsp. azalomyceticus (ATCC13810), and subsp. jinggangensis (Yu, Y. et al., (2005). Appl. Environ. Microbiol., 71(9), 5066-5076.), subsp. aabomyceticus (ATCC21449) strain, and subsp. hialomyceticus (NBRC13946) strain.
[0036] <2> Enhancement of phosphoenolpyruvate synthase activity The term "modified to enhance phosphoenolpyruvate synthase activity in cells" may mean that the bacterium has been modified to increase the expression level and / or total activity of phosphoenolpyruvate synthase, or to overexpress the gene encoding phosphoenolpyruvate synthase, i.e., to have a higher expression level (i.e., expression amount) of the gene encoding phosphoenolpyruvate synthase, in the modified bacterium, compared to the unmodified bacterium. The term "unmodified bacterium" may mean a bacterial strain that can be a control for the above comparison. "Unmodified bacterium" is also referred to as "unmodified strain" or "unmodified bacterial strain." Unmodified bacterial strains include wild-type strains and parent strains of bacteria belonging to the genus Streptomyces (e.g., Streptomyces viridochromogenes). A specific example of an unmodified bacterial strain is the Streptomyces viridochromogenes JCM4977 strain. can be.
[0037] As the "gene encoding phosphoenolpyruvate synthase", a gene from a bacterium of the genus Streptomyces or a gene derived from other organisms such as Escherichia coli can be used.
[0038] The "gene encoding phosphoenolpyruvate synthase" is preferably a polynucleotide having a base sequence of SEQ ID NO: 1, or a polynucleotide having a base sequence that hybridizes to its complementary sequence under stringent conditions and encodes a protein having phosphoenolpyruvate synthase activity. The base sequence of SEQ ID NO:1 is the base sequence of the gene (ppsA gene) encoding phosphoenolpyruvate synthase of Streptomyces viridochromogenes.
[0039] The ppsA gene can be obtained by PCR using primers prepared based on the nucleotide sequence of SEQ ID NO: 1, such as the primers shown in SEQ ID NO: 9 and 10, and the genomic DNA of Streptomyces viridochromogenes as a template. Genes encoding phosphoenolpyruvate synthase of other microorganisms, such as Escherichia coli, can also be obtained in a similar manner.
[0040] "Stringent conditions" refer to conditions under which so-called specific hybrids are formed and non-specific hybrids are not formed. For example, two DNAs with high identity, preferably two DNAs with an identity of 80% or more, more preferably 90% or more, particularly preferably 95% or more, hybridize with each other, but two DNAs with lower identity do not hybridize. For example, the conditions include conditions under which the hybridization is performed once, preferably twice to 3 times, at a salt concentration and temperature corresponding to 60°C, 0.1×SSC, 0.1% SDS, more preferably 68°C, 0.1×SSC, 0.1% SDS. Examples of conditions include washing three times. That is, the gene encoding phosphoenolpyruvate synthase may have a base sequence that has 80% or more, more preferably 90% or more, and particularly preferably 95% or more identity with the base sequence of SEQ ID NO: 1, so long as it encodes a protein having phosphoenolpyruvate synthase activity.
[0041] Furthermore, the "gene encoding phosphoenolpyruvate synthase" may have a nucleotide sequence containing one or several nucleotide substitutions, deletions, insertions, or additions in the nucleotide sequence of SEQ ID NO: 1, so long as it encodes a protein having phosphoenolpyruvate synthase activity. Here, one or several means, for example, 1 to 50, 1 to 30, 1 to 10, or 1 to 5. The "gene encoding phosphoenolpyruvate synthase" may be a partial sequence in which the 5'-end and / or 3'-end of the nucleotide sequence of SEQ ID NO: 1 has been deleted, so long as it encodes a protein having phosphoenolpyruvate synthase activity.
[0042] The "protein having phosphoenolpyruvate synthase activity" is preferably a protein comprising the amino acid sequence of SEQ ID NO: 2, or an analogue of the protein comprising the amino acid sequence of SEQ ID NO: 2. That is, the Streptomyces bacterium of the present invention is preferably modified to increase the expression level and / or total activity of phosphoenolpyruvate synthase, thereby enhancing phosphoenolpyruvate synthase activity, and the phosphoenolpyruvate synthase is preferably a protein comprising the amino acid sequence of SEQ ID NO: 2, or an analogue of the protein comprising the amino acid sequence of SEQ ID NO: 2. The amino acid sequence of SEQ ID NO: 2 is the amino acid sequence of phosphoenolpyruvate synthase encoded by the ppsA gene. The amino acid sequence of SEQ ID NO: 2 is shown in Table 1.
[0043] [Table 1] In the table, the amino acid sequences are listed from left to right from N-terminus to C-terminus.
[0044] An "analog of a protein containing the amino acid sequence of SEQ ID NO:2" is an analog of a protein that has one or several amino acid residues substituted, deleted, inserted, and / or added compared to the amino acid sequence shown in SEQ ID NO:2. A protein that has one or more modifications in its sequence, whether addition or deletion. In this context, the term "modified phosphoenolpyruvate synthase" may refer to a protein that maintains the activity or function of unmodified phosphoenolpyruvate synthase, or whose three-dimensional structure has not been significantly altered compared to unmodified phosphoenolpyruvate synthase (e.g., a protein comprising the amino acid sequence shown in SEQ ID NO: 2). The number of modifications in an analog protein depends on the position of an amino acid residue in the three-dimensional structure of the protein or the type of amino acid residue. The number of modifications in an analog protein is not strictly limited, but may be 1 to 30 in SEQ ID NO: 2, 1 to 20 in another example, or 1 to 30 in another example. In another example, the amino acids may be 1 to 15, in another example, 1 to 10, or in another example, 1 to 5. This is because the modification between the amino acids may have a high homology to the entire amino acid sequence of SEQ ID NO:2, and the activity or function of the protein may not be affected or the three-dimensional structure of the protein may not be significantly changed compared to the unmodified protein, depending on the modification between the amino acids. Therefore, an analog protein is an amino acid having 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more homology to the entire amino acid sequence of SEQ ID NO:2, as long as the activity or function of phosphoenolpyruvate synthase is maintained or the three-dimensional structure of the protein is not significantly changed compared to the unmodified phosphoenolpyruvate synthase (e.g., a protein including the amino acid sequence shown in SEQ ID NO:2). The protein may be a protein having an amino acid sequence.
[0045] The expression "phosphoenolpyruvate synthase activity is enhanced" may mean that the total amount and / or activity of phosphoenolpyruvate synthase is increased compared to an unmodified bacterial strain. The total amount and / or activity of phosphoenolpyruvate synthase can be increased, for example, by increasing the expression level of the gene encoding phosphoenolpyruvate synthase compared to an unmodified bacterial strain (i.e., overexpressing the gene encoding phosphoenolpyruvate synthase) or by increasing the activity per molecule of phosphoenolpyruvate synthase (also called specific activity) compared to an unmodified bacterial strain. The increase in the total amount or activity of phosphoenolpyruvate synthase can be measured, for example, as an increase in the amount and / or activity of phosphoenolpyruvate synthase per cell (which may be the average amount and / or activity of phosphoenolpyruvate synthase per cell). The bacterium can be modified such that the amount and / or activity of phosphoenolpyruvate synthase per cell is increased, for example, to 150% or more, 200% or more, or 300% or more of the amount and / or activity in a non-modified bacterial strain. Phosphoenolpyruvate synthase activity can be measured, for example, by measuring the concentration of AMP produced when phosphoenolpyruvate synthase is reacted with pyruvate as a substrate. Phosphoenolpyruvate synthase activity can also be evaluated by measuring the amount of phosphoenolpyruvate synthase, which can be measured by known methods such as SDS-PAGE followed by immunoblotting (Western blotting) or mass spectrometry of protein samples.
[0046] Also, the expression "the gene encoding phosphoenolpyruvate synthase is overexpressed" can mean that the expression level (i.e., the amount of expression) of the gene encoding phosphoenolpyruvate synthase is higher than that in the unmodified bacterial strain. Thus, the term "the gene encoding phosphoenolpyruvate synthase is overexpressed" can be used interchangeably or equivalently with the term "the expression of the gene encoding phosphoenolpyruvate synthase is enhanced or increased". The increase in the expression level of the gene encoding phosphoenolpyruvate synthase can be measured, for example, as an increase in the expression level of the gene per cell (which may be the average expression level of the gene per cell). The bacterium can be modified such that the expression level of the gene encoding phosphoenolpyruvate synthase per cell is increased, for example, to 150% or more, 200% or more, or 300% or more than the expression level in the unmodified bacterial strain.
[0047] Methods that can be used to enhance the expression of the gene encoding phosphoenolpyruvate synthase include, but are not limited to, increasing the copy number of the gene encoding phosphoenolpyruvate synthase, for example, the copy number of the gene in the bacterial chromosome and / or the copy number of the gene in an autonomously replicating plasmid carried by the bacterium.The copy number of the gene can be increased, for example, by introducing the gene into the bacterial chromosome and / or introducing an autonomously replicating plasmid containing the gene into the bacterium.Such modification of Streptomyces bacteria can be carried out by genetic engineering techniques well known to those skilled in the art.
[0048] Vectors include, but are not limited to, plasmids such as pGM1190, pSET152, pKC1139, SCP2, SLP1.2, and pIJ101. The gene to be transduced can also be introduced into the bacterial chromosomal DNA by, for example, homologous recombination. The gene encoding phosphoenolpyruvate synthase may be introduced in one copy, or in two or more copies. For example, multiple copies of the gene encoding phosphoenolpyruvate synthase can be introduced into the chromosomal DNA by performing homologous recombination using a sequence having multiple copies in the chromosomal DNA. Examples of sequences having multiple copies in the chromosomal DNA include, but are not limited to, repetitive DNA and inverted repeats present at the ends of transposable elements. Furthermore, multiple copies of the gene encoding phosphoenolpyruvate synthase can be introduced into the chromosomal DNA by incorporating the gene into a transposon and transferring the gene.
[0049] Another method that can be used to enhance the expression of a gene encoding phosphoenolpyruvate synthase is to increase the expression level of the gene by modifying the expression control region of the gene encoding phosphoenolpyruvate synthase. The expression control region of the gene can be, for example, modified from the native expression control region of the gene to a wild type. The expression control region can be modified by introducing a foreign expression control region of the same type and / or modified form. The "expression control region" is also called an "expression control sequence." The expression control region includes promoters, enhancers, attenuators and termination signals, antitermination signals, ribosome binding sites (RBS), and other expression control elements (e.g., repressors or The region may be a region to which an inducer binds, and / or, for example, a binding site for a transcriptional and translational regulatory protein in the transcribed mRNA. Such regulatory regions are, for example, those described in Sambrook J., Fritsch EF and Maniatis T., "Molecular Cloning: A Laboratory Manual ", 2nd ed., Cold Spring Harbor Laboratory Press (1989). Modification of the expression control region of the gene encoding phosphoenolpyruvate synthase may be combined with an increase in the copy number of the gene encoding phosphoenolpyruvate synthase.
[0050] Examples of promoters suitable for enhancing the expression of a gene encoding phosphoenolpyruvate synthase include strong promoters stronger than the native ppsA promoter, such as the lac promoter, the trp promoter, the trc promoter, the tac promoter, the tet promoter, the araBAD promoter, the rpoH promoter, the msrA promoter, the Pm1 promoter (derived from the genus Bifidobacterium), and the PR and PL promoters of lambda phage. Promoters known to be strong promoters such as the pmi promoter Additionally, a strong promoter that confers a high level of gene expression in Streptomyces bacteria can be used.
[0051] Preparation of plasmid DNA, DNA cleavage, DNA ligation, DNA transformation, selection of oligonucleotides as primers, introduction of mutations, etc. Methods for cloning may be conventional methods well known to those skilled in the art. Such methods are described, for example, in Sambrook J., Fritsch EF and Maniatis T., "Molecular Cloning: Laboratory Manual”, 2nd ed., Cold Spring Harbor Laboratory Press (1989), or Green MR and Sambrook JR, “Molecular Cloning: A Laboratory Manual”, 4th ed., Cold Spring Harbor Laboratory Press (2012), or Bernard R. Glick, Jack J. Pasternak and Cheryl L. Patten, “Molecular Biotechnology: principles and applications of recombinant DNA”, 4th ed., Washington, DC, ASM Press (2009).
[0052] Recombinant DNA manipulation techniques include, for example, transformation, transfection, and immunization. Any method can be used, including conventional methods such as transformation, transfection, infection, conjugation, or mobilization of bacteria with DNA encoding the protein. By this, the bacterium is endowed with the ability to synthesize the protein encoded by the DNA. Methods of transformation, transfection, infection, conjugation, and mobilization can include any method.
[0053] In addition to the above-mentioned properties, the bacteria may have specific properties such as various nutritional requirements, drug resistance, drug sensitivity, drug dependency, etc., without departing from the scope of the present invention.
[0054] The copy number of the gene encoding phosphoenolpyruvate synthase, and the presence or absence of the gene can be determined, for example, by restriction of chromosomal DNA followed by the use of a probe based on the gene sequence. Southern blotting, fluorescent in situ hybridization (FISH), etc. The level of gene expression can be determined by measuring the amount of mRNA transcribed from the gene using a variety of well-known methods, such as Northern blotting or quantitative RT-PCR.
[0055] The Streptomyces bacterium of the present invention has been modified to enhance intracellular phosphoenolpyruvate synthase activity, thereby increasing production of a physiologically active substance having a CP bond. It can be strengthened. "The production of a physiologically active substance having a CP bond is enhanced" in the modified bacterium. It is meant that the production amount of a physiologically active substance having a CP bond is increased compared to that of a non-modified bacterium. Specifically, for example, the modified bacterium may produce a physiologically active substance having a CP bond in a medium or in a medium containing 1.1 times or more, 1.3 times or more, or 1.5 times or more of the physiologically active substance as compared with the non-modified bacterium. The term "unmodified bacteria" may refer to a bacterial strain that can be a control for the above comparison. Examples of the bacterial strain include wild-type strains and parent strains of bacteria belonging to the genus Streptomyces (e.g., Streptomyces viridochromogenes). A specific example of an unmodified bacterial strain is the Streptomyces viridochromogenes JCM4977 strain. The physiologically active substance having a CP bond, the production of which is enhanced, may be a physiologically active substance having one or more types of CP bonds.
[0056] The production amount of a physiologically active substance having a CP bond, such as bialaphos, can be measured by a known method. For example, a physiologically active substance having a CP bond that has accumulated in the medium or in the bacterial cells can be measured by LC-MS / MS.
[0057] <3> Method for producing physiologically active substances having CP bonds The method for producing a physiologically active substance having a CP bond of the present invention is carried out by using the Streptomyces sp. Bacteria are cultured in a culture medium, and bioactive substances with CP binding are detected in the culture medium and / or in the bacteria. The physiologically active substances having CP bonds include those mentioned above. The biologically active substances having a CP bond can be produced in particular in the free form or in the form For example, a physiologically active substance having a CP bond may be prepared as a salt or a mixture thereof. Salts such as sodium, potassium, ammonium, etc. of the compound can be prepared by the above method.
[0058] In addition, the method for producing a physiologically active substance having a CP bond of the present invention is Bacteria of the genus Sesbacterium were cultured in a culture medium to identify CP-binding physiological species in the culture medium and / or in the cells. After the active substance is produced and accumulated, the CP bond is extracted from the culture medium and / or the cells. The method may optionally include a step of purifying the bioactive substance having CP binding from the culture medium and / or the bacterial cells.
[0059] Cultivation of bacteria and optionally recovery of CP-binding bioactive substances from the medium, etc. The purification and purification processes are the same as those of conventional fermentation methods that use microorganisms to produce bioactive substances with CP bonds. The same can be carried out. The culture medium may be a synthetic or natural medium, such as a typical medium containing a carbon source, a nitrogen source, a sulfur source, a phosphorus source, inorganic ions, and other organic and inorganic components as necessary. As carbon sources, sugars such as glucose, sucrose, lactose, galactose, fructose, arabinose, maltose, xylose, trehalose, ribose, starch hydrolysates, alcohols such as ethanol, glycerol, mannitol, sorbitol, organic acids such as gluconic acid, fumaric acid, citric acid, malic acid, succinic acid, and fatty acids can be used. As nitrogen sources, inorganic ammonium salts such as ammonium sulfate, ammonium chloride, and ammonium phosphate, organic nitrogen such as soybean hydrolysates, ammonia gas, and aqueous ammonia can be used. In addition, peptone, yeast extract, meat extract, malt extract, corn steep liquor, cottonseed cake, and the like can also be used. The medium may contain one or more of these nitrogen sources. Examples of sulfur sources include ammonium sulfate, magnesium sulfate, iron sulfate, manganese sulfate, etc. The medium may contain a phosphorus source in addition to the carbon source, nitrogen source, and sulfur source. Examples of phosphorus sources that can be used include potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and phosphate polymers such as pyrophosphate. Vitamins such as vitamin B1, vitamin B2, vitamin B6, nicotinic acid, nicotinamide, and vitamin B12, and other necessary substances, such as adenine, nucleic acids such as RNA, amino acids, peptones, casamino acids, and organic nutrients such as yeast extract, may be added in appropriate amounts (without trace amounts). In addition to these, small amounts of calcium phosphate, iron ions, manganese ions, etc. may be added, if necessary.
[0060] The cultivation is carried out under conditions suitable for the cultivation of bacteria used in the production method of a physiologically active substance having a CP bond. For example, the culture can be carried out under aerobic conditions for 16 to 72 hours, or 16 to 24 hours. The culture temperature during the culture can be controlled within the range of 28 to 45° C., or 28 to 37° C. The pH can be adjusted between 5 and 8, or between 6 and 7.5. The pH can be adjusted by using an inorganic or organic acidic or alkaline substance, such as urea, calcium carbonate, or ammonia gas.
[0061] After the culture, the physiologically active substance having a CP bond can be collected from the culture medium. After the cultivation, a physiologically active substance having a CP bond can be collected from the bacterial cells. The cells are disrupted, solid matter such as the cells and cell-disrupted suspension (also called cell debris) is removed to obtain the supernatant, from which the physiologically active substance having a CP bond can be recovered. The removal of solids can be carried out by, for example, centrifugation or membrane filtration. The recovery of a physiologically active substance having a CP bond from a culture medium or a supernatant can be carried out by, for example, concentration, crystallization, ion exchange, or the like. This can be carried out by conventional techniques such as conversion chromatography, medium or high pressure liquid chromatography, or a combination thereof.
[0062] The recovered physiologically active substance having a CP bond may contain, in addition to the physiologically active substance having a CP bond, for example, bacteria, medium components, water, metabolic by-products of the microorganism, etc. The biologically active substance having the bond may be purified to a desired degree. The purity of the physiologically active substance may be, for example, 50% or more, preferably 85% or more, and particularly preferably 95% or more. EXAMPLES
[0063] Examples of the present invention will be described below, but the present invention is not limited to these examples.
[0064] [Example 1: Metabolomic analysis of prototype strains] A strain with one additional copy of the bialaphos biosynthetic enzyme gene cluster (prototype strain: reference example described later) and a wild-type strain (Streptomyces viridochromogenes ( S. viridochromogenes ) strain JCM4977) was used to evaluate bialaphos productivity and perform metabolomic analysis. (1) Jar culture 150 ml of YS medium (1% by weight soluble starch, 0.2% by weight yeast extract) was placed in a 500 ml The prototype strain and the wild-type strain were inoculated into a flask with a bluff, and pre-preculture (28°C, 135 rpm) was carried out for 2 days. Then, 10 ml of the pre-preculture solution was added to 150 ml of MYG medium (1% by weight of malt) and mixed for 2 days. Extract, 0.4% by weight yeast extract, 0.4% by weight glucose) in a 500 ml baffled flask. The bacteria were inoculated into a 1 L flask and pre-cultured at 28°C and 135 rpm for 1 day. The bacteria were inoculated into a jar culture medium (0.4% by weight glucose, 1.5% by weight malt extract, 1.2% by weight yeast extract, 0.0001% by weight CoCl2·6H2O) and incubated in a 2L jar fermenter at 28°C, pH 7.4, and The culture was carried out for 12 days under the condition of 1 slpm (1 L / min) of aeration. Note that the dissolved oxygen concentration was controlled to 0.5 ppm from the 4th day of culture onwards. In addition, 50 ml of supplemented medium (20% by weight glucose, 10% by weight yeast extract, 0.2% by weight KH2PO4) was added on the 5th, 6th, 7th and 10th days.
[0065] (2) Measurement of bialaphos production After jar cultivation, the wild type and prototype strains were analyzed by LC-MS / MS. The concentration of bialaphos secreted into the culture supernatant was measured.
[0066] (3) Metabolomic analysis After jar cultivation, cells were collected from the culture medium of each of the wild-type and prototype strains, quickly cooled in liquid nitrogen, and metabolites were extracted using methanol / chloroform / water. Metabolic analysis was performed by LC-MS / MS.
[0067] (4) Results The measurement results of the amount of bialaphos produced are shown in Figure 2. As shown in Figure 2, the prototype strain was shown to have higher bialaphos productivity than the wild-type strain. In addition, as a result of metabolome analysis, the accumulation amount of main compounds in the central metabolic pathway is shown in Figure 3. In the prototype strain, the accumulation amount of PEP was The results of the measurement of bialaphos production and metabolome analysis showed that PEP, an intermediate raw material of bialaphos, and The amount of bialaphos accumulated was negatively correlated with the amount of PEP, suggesting that the consumption of PEP is promoted in the prototype strain where bialaphos is highly produced. They speculated that increasing the amount of PEP could improve bialaphos productivity. .
[0068] [Example 2: Evaluation of bialaphos productivity of ppsA gene plasmid-introduced strains using bialaphos-susceptible bacteria] The autonomously replicating plasmid carrying the ppsA gene and the pmi promoter was introduced into the prototype strain. A strain containing the plasmid (a strain containing the ppsA gene plasmid) was prepared, and the productivity of bialaphos was evaluated by performing a growth inhibition assay of the strain against bialaphos-susceptible bacteria.
[0069] (1) Construction of strains carrying the ppsA gene plasmid (Construction of plasmids) First, the apramycin resistance gene of the autonomously replicating plasmid pGM1190 (addgene, #69994) A plasmid (pGK) was constructed in which the kanamycin resistance gene was replaced with the apramycin resistance gene. Specifically, inverse PCR was performed using pGM1190 as a template and I-44 primer (sequence number 5) and I-45 primer (sequence number 6), and the apramycin resistance gene was inserted to replace the drug resistance marker. The resulting DNA fragment was digested with NsiI and SpeI to introduce an NsiI site and an SpeI site. The NsiI-NheI fragment of the kanamycin resistance gene was inserted into the treated plasmid. The isin resistance gene was constructed by amplifying it by PCR using pRI909 (Takarabio, Code 3260) as a template and I-17 primer (SEQ ID NO: 7) and I-46 primer (SEQ ID NO: 8). Made.
[0070] Streptomyces viridochromogenes ( S. viridochromogenes )Genotype of JCM4977 strain The I-162 primer (SEQ ID NO: 9) and the I-163 primer (SEQ ID NO: 1) were used as a template. 10) was used to amplify the ppsA gene (sequence number 1) by PCR.
[0071] Using the genomic DNA of the JCM4977 strain as a template, the pmi promoter fragment (SEQ ID NO: 4) was amplified by PCR using the I-48 primer (SEQ ID NO: 11) and the I-49 primer (SEQ ID NO: 12).
[0072] pSET152 (Creative Biogene, Cat. No. OVT2796) was used as a template, and the I-54 primer ( Using the PCR primer (sequence number 13) and I-55 primer (sequence number 14), the transcription terminator region (sequence number 3) derived from pSET152 was amplified by PCR.
[0073] The obtained EcoRI-NsiI fragment of the pmi promoter, the NsiI-SpeI fragment of the ppsA gene, and the XbaI-HindIII fragment of the transcription terminator region derived from pSET152 were inserted into the EcoRI-HindIII gap of pGK. Inserted into.
[0074] Table 2 shows the nucleotide sequences of the ppsA gene, promoter, and terminator, and Table 3 shows the nucleotide sequences of the primers used.
[0075] [Table 2] In Table 2, the sequences are oriented from left to right from 5' to 3'.
[0076] [Table 3] In Table 3, the sequences are oriented from left to right from 5' to 3'.
[0077] (Transformation of E. coli for conjugation) Each of the constructed plasmids was used to transform E. coli by electroporation according to the following procedure. First, competent cells of the E. coli S17-1 strain were prepared by the following procedure. Streaking the glycerol stock of E. coli S17-1 on an LB plate, then incubating at 37°C for 16-20 hours. A single colony was obtained by inoculating the single colony into 2.5 mL of LB medium and incubated at 37 °C. The mixture was pre-cultured at 37°C, 200 rpm for 16 hours. 200 μl of the pre-culture was inoculated into 20 mL of LB medium and incubated at 37°C, 200 rpm for 16 hours at OD 600 The bacteria were harvested by centrifugation (4°C, 3000 xg, 10 min). Then, discard the supernatant, add 20 mL of ice-cold sterile water, and gently suspend the pellet with a pipette. After repeating the steps of collecting and washing the bacteria once more, the bacteria were collected again by centrifugation (4°C, 3000 xg, 10 min), the supernatant was discarded, and the pellet was gently suspended in 200 μl of ice-cold 10% glycerol using a pipette. 50 μl of this suspension was added to each tube (Eppendorf tube). Competent cells of the S17-1 strain were prepared by dispensing the cells into a culture flask (manufactured by Eppendorf).
[0078] The constructed plasmid (~2 μL) was added to the prepared competent cells and electroporated. The cells were transferred to a poration cell (Bio-Rad Laboratories, Inc.) and then left to stand on ice for 10 minutes. An electric pulse of 1.8 kV, 25 μF, and 200 Ω was applied, and 1 mL of LB medium was added. The cells were then harvested at 20,000 xg for 1 minute, the supernatant was removed, and the cells were resuspended in an appropriate amount of medium and plated on 2xYT agar medium containing 100 μg / mL kanamycin. The mixture was then smeared onto the soil and incubated overnight at 37°C. In addition, the same procedure was followed except that an empty vector (pGK) was used instead of the constructed plasmid. E. coli was transformed in each order and cultured as a negative control.
[0079] (Transformation of Streptomyces bacteria) The transformed E. coli was used to transform Streptomyces bacteria by conjugal transfer according to the following procedure. The E. coli S17-1 strain carrying the transformation plasmid obtained by the above culture was diluted to 100 μg / mL. The bacteria was inoculated into 2 mL of LB medium containing 100 μg / mL kanamycin and precultured overnight at 37°C and 200 rpm. 100 μL of the preculture was inoculated into 10 mL of fresh LB medium (containing 100 μg / mL kanamycin) and the OD 600 The cells were cultured at 37°C and 200 rpm until the pH reached 0.4-0.8. The cells were harvested at 8000 xg for 10 minutes, the supernatant was discarded, and the harvested cells were suspended (washed) in 10 mL of LB medium by pipetting. The above process was repeated twice to remove the antibiotics contained in the culture medium. The collected bacterial pellet was then resuspended in 1 mL of LB medium. 500 μL of this E. coli suspension was then added to 500 mL of LB medium. The cells were suspended in 10 μl of 2×YT medium, heat-shocked at 50°C for 10 minutes, and then left to stand on ice. The spores were mixed with the prototype strain spores and centrifuged briefly. Culture medium (2% by weight agar, 1% by weight starch, 0.2% by weight calcium carbonate, 0.2% by weight ammonium sulfate, 0.1% by weight dipotassium hydrogen phosphate, 0.1% by weight magnesium sulfate heptahydrate, 0.1% by weight sodium chloride, 0.1% by weight yeast extract, 0.0001% by weight iron(II) sulfate heptahydrate) , 0.0001 wt% manganese chloride heptahydrate, and 0.0001 wt% zinc sulfate heptahydrate) and cultured at 28°C for about two weeks to obtain the actinomycetes. After the above centrifugation, the supernatant was discarded, leaving about 50 μL, and the bacterial pellet was resuspended in the remaining supernatant, and then a dilution series was prepared with sterile water, and 100 μL was applied to 20 ml of ISP4 plate medium and cultured overnight at 28° C. 0.5 mg of nalidixic acid and 10 μl of 100 mg / mL kanamycin were added to 1 ml of sterile water, which was then layered on the medium and cultured at 28° C. for an additional 3 to 5 days to obtain a transformant of Streptomyces bacteria (a strain with a ppsA gene plasmid introduced). In addition, E. coli transformed with an empty vector (pGK) was used in the same procedure. A transformant of Streptomyces bacteria (empty vector-introduced strain) was obtained.
[0080] (2) Growth inhibition assay for bialaphos-susceptible bacteria Nutrient agar (0.5% by weight peptone, 0.3% by weight yeast extract, 0.5% by weight salt Bialaphos-sensitive Bacillus subtilis ATCC6633 strain, which had been cultured overnight at 35°C in 0.8% by weight Bacto nutrient broth, 0.01% by weight potassium chloride, 0.0012% by weight magnesium sulfate, 1 mM Ca(NO3)2, 0.01 mM MnCl2, 1 mM FeSO4, pH 7.6, was inoculated into 5 mL of DSM medium (0.8% by weight Bacto nutrient broth, 0.01% by weight potassium chloride, 0.0012% by weight magnesium sulfate, 1 mM Ca(NO3)2, 0.01 mM MnCl2, 1 mM FeSO4, pH 7.6) and cultured in a test tube at 37°C and 150 rpm for 24 hours. The culture was diluted with sterile water to obtain OD 600 The pH was adjusted to 3.0, and 150 μL was added to the assay medium (0.3 wt% KH2PO4, 0.7 wt% K2HPO4, 0.05 wt% Na citrate 2H2O, 0.01 wt% MgSO4 7H2O, 0.1 wt% The tissue was then evenly coated with a solution of 0.2% (NH4)2SO4 by weight, 0.2% glucose by weight, and 1.2% agar by weight and then left to dry for 15 minutes. The culture medium of the ppsA gene plasmid-introduced strain and the culture medium of the empty vector-introduced strain obtained by the above transformation were appropriately diluted, and 5 μL of each was spotted on a sterilized paper disc and air-dried. After that, they were placed at equal intervals on the test medium and cultured overnight at 35°C. The diameter of the inhibition zone of Bacillus subtilis formed was measured at three points, and the average value was used to evaluate the productivity of bialaphos. .
[0081] (3) Results The results of the growth inhibition assay are shown in Figures 4 and 5. Figures 4 and 5 show that when the ppsA gene plasmid-introduced strain was spotted, the diameter of the inhibition zone was about two times larger than that of the empty vector-introduced strain.
[0082] [Example 3: Evaluation of bialaphos productivity in strains with ppsA gene plasmid introduced] The amount of bialaphos produced by the strain into which the ppsA gene plasmid obtained in Example 2 was introduced was measured.
[0083] (1) Flask culture The ppsA gene plasmid-introduced strain and the empty vector-introduced strain obtained in Example 2 were each cultured in a 500 ml volume of YS medium (1% by weight soluble starch, 0.2% by weight yeast extract) containing 150 ml. The bacteria was inoculated into a baffled flask and pre-cultured at 140 rpm for 3 days at 28° C. 1 ml of the pre-culture solution was inoculated into a 500 ml baffled flask containing 150 ml of MYG medium (1 wt % malt extract, 0.4 wt % yeast extract, 0.4 wt % glucose) containing 12.5 mg / L kanamycin and cultured at 28° C. for 6 days. The culture was performed at 140 rpm until the third day of culture, and at 85 rpm thereafter.
[0084] (2) Measurement of bialaphos production The amounts of bialaphos produced in the ppsA gene plasmid-introduced strain and the empty vector-introduced strain were measured in the same manner as in "(2) Measurement of bialaphos production amount" of Example 1.
[0085] (3) Results The measurement results of the amount of bialaphos produced are shown in Figure 6. It was shown that the strain into which the ppsA gene plasmid had been introduced produced a significantly higher amount of bialaphos than the strain into which the empty vector had been introduced.
[0086] [Example 4: Evaluation of bialaphos productivity of strains with ppsA gene introduced into the genome] We evaluated the productivity of bialaphos in a strain in which the ppsA gene was introduced into the genome of Streptomyces viridochromogenes (ppsA gene genome-introduced strain).
[0087] (1) Construction of a strain with ppsA gene introduced (Construction of plasmids) The plasmid for gene insertion into the genome was constructed based on pKC1139 (Nova Lifetech, Catalog No. PVT6009). To introduce the gene into the gene encoding a protein annotated as type I polyketide synthase in the lavendiol synthase gene cluster (Genbank accession number: WP_039933327.1), the upstream and downstream genomic regions of the gene were primer-implanted into the genome of Streptomyces viridochromogenes JCM4977 strain using I-122 primer (SEQ ID NO: 16), I-123 primer (SEQ ID NO: 17), I-124 primer (SEQ ID NO: 18), and I-125 primer (SEQ ID NO: 19), respectively. The type was amplified by PCR.
[0088] The EcoRI-SpeI fragment of the downstream region of the gene was inserted into the EcoRI-XbaI gap of pKC1139. The resulting plasmid was cleaved with EcoRI-XbaI, and an EcoRI-SpeI fragment of a kanamycin resistance gene cassette (SEQ ID NO: 15) was inserted therein. The resulting plasmid was cleaved with EcoRI-XbaI, and an EcoRI-SpeI fragment of a ppsA gene expression cassette (the plasmid prepared in "Preparation of Plasmid" in Example 2) was inserted therein. Finally, the resulting plasmid was cleaved with EcoRI-XbaI, and an EcoRI-SpeI fragment of the upstream region of the WP_039933327.1 gene was inserted therein to construct a plasmid for introducing the ppsA gene. Furthermore, in the above step, an empty vector was prepared by constructing a pKC1139 vector that did not contain the ppsA gene expression cassette, but contained the downstream region of the WP_039933327.1 gene, a kanamycin resistance gene cassette, and the upstream region of the WP_039933327.1 gene.
[0089] Table 4 shows the base sequence of the kanamycin resistance gene cassette, and Table 5 shows the base sequences of the primers used.
[0090] [Table 4] In Table 4, the sequences are oriented from left to right from the 5' end to the 3' end.
[0091] [Table 5] In Table 5, the sequences are oriented from left to right from the 5' end to the 3' end.
[0092] (Transformation of Escherichia coli for conjugation and transformation of Streptomyces bacteria) Except for using the obtained plasmid for introducing the ppsA gene and the empty vector, transformation of Escherichia coli for conjugation was performed in the same manner as in Example 2, and then transformants of Streptomyces bacteria (a strain with the ppsA gene genome introduced and an empty vector introduced) were obtained.
[0093] (2) Flask culture The ppsA gene genome-introduced strain and the empty vector-introduced strain were each cultured in a flask in the same manner as in "(2) Flask culture" of Example 3.
[0094] (3) Measurement of bialaphos production The amounts of bialaphos produced by the flask-cultured ppsA gene genome-introduced strain and the empty vector-introduced strain were measured in the same manner as in "(2) Measurement of bialaphos production amount" of Example 1.
[0095] (4) Results The results of measuring the amount of bialaphos produced are shown in Figure 7. It was shown that the strain into which the ppsA gene genome was introduced produced a significantly higher amount of bialaphos than the strain into which the empty vector was introduced.
[0096] [Reference example: Prototype strain creation] A strain (prototype strain) with one additional copy of the bialaphos biosynthetic enzyme gene cluster was The strain was prepared as follows. S. viridochromogenes) is known to have the bialaphos synthesis gene cluster shown in FIG. 8, which contains the following protein-encoding genes from the 5' end: The genes are known to exist in the following order: phpA gene, phsB gene, phpB gene, phsC gene, pmi gene, phpC gene, phpD gene, phpE gene, ppm gene, ppd gene, phpF gene, phpG gene, phpH gene, phpI gene, phpJ gene, phpK gene, pms gene, phsA gene, pat gene, dea gene, phpL gene, phpM gene, phpN gene, and phpR gene (Blodgett et al. 2016, J Antibiot (Tokyo). 69, 15-25).
[0097] (1) Construction of plasmid for gene transfer The plasmid for gene transfer was based on pSET152 (Creative Biogene, Cat. No. OVT2796). The genome DNA of Streptomyces viridochromogenes JCM4977 strain was used as a template to construct the vector. Each DNA fragment of the Sq1 to Sq6 and F3 regions of the bialaphos synthase gene cluster was The primer set shown in Table 6 was used for PCR amplification. First, the XbaI-EcoRV fragment of F3 obtained was inserted into the XbaI-EcoRV gap of pSET152 to construct a plasmid carrying F3 (F3 in FIG. 8). Next, the NheI-SbfI fragment of Sq6 and the SbfI-EcoRV fragment of F3 were inserted into the XbaI-EcoRV gap of pSET152. Next, the MunI-SpeI fragment of Sq5 was inserted into the EcoRI-XbaI gap of the plasmid into which Sq6F3 had been introduced to construct a plasmid into which Sq5-6F3 (Sq5-6F3 in FIG. 8) had been introduced was constructed. Similarly, the MunI-SpeI fragment of Sq4, the MunI-SpeI fragment of Sq3, the MunI-SpeI fragment of Sq2, and the MunI-SpeI fragment of Sq1 were each inserted, and the plasmids shown in FIG. 8 were constructed. The plasmid in which the full length of the bialaphos synthase gene cluster was introduced into pSET152. was constructed.
[0098] [Table 6]
[0099] The base sequences of the primer sets shown in Table 6 are shown in Table 7.
[0100] [Table 7] In the table, the base sequences are from left to right from the 5' end to the 3' end.
[0101] (2) Transformation of E. coli for conjugation Escherichia coli was transformed with the constructed plasmid in the same manner as in "Transformation of Escherichia coli for conjugation" in Example 2, except that 100 μg / mL apramycin was used as the antibiotic.
[0102] (3) Transformation of Streptomyces bacteria The Streptomyces bacterium to be transformed was Streptomyces viridochromogenes ( S. viridochromogenes The JCM4977 strain was used, and 100 μg / mL apramycin was used as an antibiotic for the culture of E. coli S17-1 strain, and 0.5 mg nalidixic acid and 10 μl of 100 mg / mL apramycin in 1 ml of sterile water were used for the selection of Streptomyces viridochromogenes. A prototype strain was obtained by transforming Streptomyces bacteria in the same manner as in “Transformation of Streptomyces bacteria” in Example 2, except that ramycin was added.
Claims
1. A bacterium belonging to the genus Streptomyces, which has been modified so as to enhance phosphoenolpyruvate synthase activity in its cells and has the ability to produce a physiologically active substance having a CP bond 。
2. The bacterium according to claim 1 , wherein the bacterium has been modified to overexpress a gene encoding phosphoenolpyruvate synthase in the cell, thereby enhancing the activity of the phosphoenolpyruvate synthase.
3. The bacterium according to claim 2, wherein the gene encoding phosphoenolpyruvate synthase is overexpressed by increasing the copy number of the gene encoding phosphoenolpyruvate synthase in the cell and / or by modifying the expression control region of the gene encoding phosphoenolpyruvate synthase.
4. The bacterium described in claim 2, wherein the gene encoding phosphoenolpyruvate synthase is a polynucleotide having a base sequence of SEQ ID NO: 1, or a polynucleotide having a base sequence that hybridizes under stringent conditions to its complementary sequence and encodes a protein having phosphoenolpyruvate synthase activity.
5. the phosphoenolpyruvate synthase is a protein comprising the amino acid sequence of SEQ ID NO:2 or an analogue of a protein comprising the amino acid sequence of SEQ ID NO:2; The analogue has an amino acid sequence having 85% or more homology to the entire amino acid sequence of SEQ ID NO:
2. The bacterium according to claim 1 , which is a protein having an amino acid sequence.
6. 2. The bacterium according to claim 1, which is a bacterium belonging to Streptomyces viridochromogenes or Streptomyces hygroscopicus.
7. A method for producing a physiologically active substance having a CP bond, comprising the steps of: A production method comprising culturing the bacterium according to any one of claims 1 to 6 in a culture medium to produce and accumulate a physiologically active substance having a CP bond in the culture medium and / or the bacterial cells.
8. The method for producing a physiologically active substance having a CP bond according to claim 7, wherein the physiologically active substance having a CP bond is one or more selected from the group consisting of bialaphos, L-glufosinate, dehydrophos, fosfomycin and FR900098.
9. The method for producing a physiologically active substance having a CP bond according to claim 7, wherein the physiologically active substance having a CP bond is bialaphos.
